GSK India: biopharma maker of General Medicines, Vaccines and Specialty oncology/respiratory drugs.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 169 | 169 | 169 | 169 | 169 | 169 | 169 | 169 |
| Reserves | 1.7k | 1.3k | 2.5k | 1.6k | 1.6k | 1.8k | 1.5k | 2.1k |
| Borrowings | 0 | 35 | 20 | 16 | 19 | 10 | 36 | 33 |
| Other Liabilities | 1.3k | 1.6k | 1.9k | 1.6k | 1.8k | 2.1k | 1.9k | 2.0k |
| Total Liabilities | 3.1k | 3.1k | 4.6k | 3.3k | 3.6k | 4.1k | 3.7k | 4.3k |
| AssetsFixed Assets | 758 | 387 | 331 | 330 | 321 | 284 | 291 | 281 |
| CWIP | 120 | 13 | 30 | 20 | 14 | 14 | 17 | 33 |
| Investments | 0 | 0 | 366 | 518 | 813 | 1.1k | 1.3k | 1.4k |
| Other Assets | 2.3k | 2.7k | 3.9k | 2.5k | 2.4k | 2.7k | 2.0k | 2.6k |
| Total Assets | 3.1k | 3.1k | 4.6k | 3.3k | 3.6k | 4.1k | 3.7k | 4.3k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 409 | 490 | 578 | 811 | 484 | 582 | 1.3k | 903 |
| Cash from Investing | -153 | -57 | 418 | -406 | 808 | 9 | -46 | 397 |
| Cash from Financing | -358 | -428 | -696 | -524 | -1.5k | -562 | -769 | -737 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 166 | 336 | 536 | 2.4k | 451 | 573 | 1.3k | 870 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (47.2×) and current (38.1×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 19.3% growth and a 38× exit, ₹2332 only delivers your return if you pay ₹2,521. The price is currently baking in 18% growth.
EPS grows 19.3%/yr for 5 years, then fades to 6% over 2, exits at 38×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 19.3% | 72.95 |
| FY28 | 19.3% | 87.03 |
| FY29 | 19.3% | 103.83 |
| FY30 | 19.3% | 123.87 |
| FY31 | 19.3% | 147.77 |
| FY32 | 12.7% ·fade | 166.47 |
| FY33 | 6.0% ·fade | 176.46 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.